Stocks opened higher Tuesday as investors attempted to look past Federal Reserve Chair Jerome Powell's hawkish appearance on "60 Minutes." However, the main indexes ran out of steam as the session wore on as more central bankers took the wait-and-see route toward rate cuts.
The major benchmarks all closed lower Monday after Powell's Sunday night appearance on CBS' "60 Minutes" reiterated what he said following last week's Fed meeting. Specifically, Powell insisted that the Fed will not cut interest rates until it is confident inflation is sustainably moving toward the 2% central bank's target.
The S&P 500 (+0.2% at 4,954) and the Nasdaq Composite (+0.07% at 15,609) traded in negative territory for most of the afternoon after Cleveland Fed President Loretta Mester said "it would be a mistake" to cut rates too soon. "Doing so would undermine all the good work that has gone into getting inflation to this point," she said at a bankers meeting in Columbus, Ohio. Still, the two managed to eke out modest gains by the close.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Dow Jones Industrial Average outperformed, adding 0.4% to 38,521 thanks to strength in blue chip stocks Walgreens Boots Alliance (WBA, +4.3%) and Nike (NKE, +2.9%).
Palantir stock pops as artificial intelligence platform demand soars
Looking beyond Dow Jones stocks, Palantir Technologies (PLTR) soared 30.8% after the data analytics platform reported higher-than-expected fourth-quarter earnings of 8 cents per share. Revenue of $608 million also beat estimates. And while the company guided for lower-than-anticipated first-quarter revenue, its full-year forecast is higher than Wall Street is expecting.
Additionally, in Palantir's subsequent earnings call, Chief Revenue Officer and Chief Legal Officer Ryan Turner noted that demand for Palantir's Artificial Intelligence Platform (AIP) is "off the charts." This is evidenced by the 103 deals closed in the fourth-quarter that are worth at least $1 million each.
"We are impressed with AI Platform ramping faster than our initial expectations and believe it's appropriate to upgrade shares to reflect the momentum," said Jefferies analyst Brent Thill, who lifted his rating on PLTR stock to Hold from Underperform (Sell). Thill also said he's encouraged by Palantir's full-year free cash flow guidance – a first for the company – of $800 million to $1 billion.
Weight-loss drugs give Eli Lilly's Q4 results a boost
Eli Lilly (LLY, -0.2%) was another notable name in the earnings spotlight. The drugmaker's foray into the weight-loss drug market helped it deliver impressive fourth-quarter results, with earnings per share soaring 19% year-over-year to $2.49. Revenue surged 28% to $9.4 billion. Both figures beat analysts' estimates.
The company's financial results were boosted in part by sales for its type 2 diabetes drug Mounjaro, which rose to $2.2 billion from $279 million in the year-ago period. Revenue from its weight-loss drug Zepbound, which launched in early December, was $175.8 million.
These drugs have also helped boost LLY's share price, with the healthcare stock more than doubling over the past 12 months. And with a $668.7 billion market cap, Eli Lilly is now one of the world's most valuable companies.
Related content
- Amazon To Raise MGM+ Streaming Service Prices
- How to Earn a Decent Yield From Your Sweep Account
- Kiplinger's Earnings Calendar for This Week (Feb. 5-9)
-
Find the Right Health Plan During Open EnrollmentYou may face sharply higher out-of-pocket costs for health care next year. Use our guide to select an insurance plan that meets your needs at the best price.
-
Trump Deal: Medicare to Cover Obesity Drugs for as Little as $50. What You Need to KnowTrump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.
-
Here's How to Plan This Year's Roth Conversion, From a Wealth ManagerWhile time is running out to make Roth conversions before the end of the taxable year, consider taking your time and developing a long-term strategy.
-
Four Times You Need a Second Opinion on Your Financial PlanIs your financial plan fit for purpose — or is your adviser peddling an outdated strategy? When you see these red flags, it's time for a second opinion.Evan
-
'But It's Not My Fault!': Your Insurance Company Absolutely Will Blame You in These Five ScenariosInsurance companies care about 'fault' in more ways than you think — from payment mishaps to your neighbor's landscaping — so it's on you to manage the risks.
-
Dow Dives 797 Points as Government Opens: Stock Market TodayThe process of pricing and re-pricing realities old and new never stops, and next week promises to be at least as exciting as this week.
-
5 Core Stocks Every Investor Should Own In 2026 and BeyondCore stocks are solid, long-term investments that provide stable returns and steady growth within your portfolio. Here are five we like.
-
How to Calm Your Retirement Nerves When It's Time to Shift from Savings Mode to Spending ModeTransitioning from saving to spending in retirement can be tricky, but devising a strategic plan can help ensure a smooth and worry-free retirement.
-
Why Wills and Trusts Aren't Enough in the Great Wealth Transfer, From an Attorney Who KnowsFamilies need to prepare heirs through communication and financial know-how, or all that money could end up causing confusion, conflict and costly mistakes.
-
Private Markets for Main Street: What Financial Advisers' Clients Need to KnowWith product innovation 'democratizing' private market access for everyday investors, advisers must step up their game to educate clients on the pros and cons.
